ProCE Banner Activity

Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates

Podcast Episodes
In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the latest results from ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostatic cancer.

Released: April 19, 2021

Expiration: April 18, 2022

Share

Faculty

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Joaquin Mateo

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Karim Fizazi, MD, PhD, has disclosed that he has received consulting fees from AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, CureVac, ESSA, Genentech, Janssen, MSD, Orion, and Sanofi.

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Joaquin Mateo, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Clovis, Guardant Health, Janssen, MSD, Pfizer, and Roche; funds for research support from AstraZeneca; and fees for non-CME/CE services from AstraZeneca, Guardant Health, Janssen, MSD, and Pfizer.